Category: Health

  • Human neurons continue to migrate after birth

    {Previously unrecognized stage of brain development discovered.}

    Researchers at UC San Francisco have discovered a previously unknown mass migration of inhibitory neurons into the brain’s frontal cortex during the first few months after birth, revealing a stage of brain development that had previously gone unrecognized. The authors hypothesize that this late-stage migration may play a role in establishing fundamentally human cognitive abilities and that its disruption could underlie a number of neurodevelopmental diseases.

    Most neurons of the cerebral cortex — the outermost layer of the brain responsible for advanced cognition — migrate outward from their birthplaces deep in the brain to take up their positions within the cortex. Developmental neuroscientists have long thought that most neural migration ends well before an infant is born, but the new paper — published October 6, 2016 in Science — suggests for the first time that many neurons continue to migrate and integrate into neural circuits well into infancy.

    “The dogma among developmental neuroscientists was that after birth all that was left was the fine wiring and pruning,” said Mercedes Paredes, MD, PhD, an assistant professor of neurology at UCSF and leader of the new study. “These results suggest there’s a whole new phase of human brain development that we had never noticed before.”

    Study of donated brain tissue unveils massive neural migration after birth

    The new study was a collaboration between the labs of co-senior authors Arturo Alvarez-Buylla, PhD, a UCSF professor of neurological surgery who specializes in understanding the migration of immature neurons in the developing brain, and in whose lab Paredes is a postdoctoral researcher, and Eric J. Huang, MD, PhD, a professor of pathology and director of the Pediatric Brain Tissue Bank at the UCSF Newborn Brain Research Institute.

    Several recent studies — including work by Alvarez-Buylla and Huang — identified small populations of immature neurons deep in the front of the brain that migrate after birth into the orbito-frontal cortex — a small region of the frontal cortex just above the eyes. Given that the entire frontal cortex continues to expand massively after birth, the researchers sought to discover whether neural migration continues after birth in the rest of the frontal cortex.

    The team examined brain tissue from the Pediatric Brain Tissue Bank using histological stains for migratory neurons. These studies revealed clusters of immature, migratory neurons widely distributed deep within the frontal lobe of the newborn brain, above the fluid-filled lateral ventricles. MRI imaging of the three-dimensional structure of these clusters revealed a long arc of migratory neurons sitting like a cap in front and on top of the ventricles and stretching from deep behind the eyebrows all the way to the top of the head.

    “Several labs had observed that there seemed to be many young neurons around birth along the ventricles, but no one knew what they were doing there,” said Paredes. “As soon as we looked closely, we were shocked to discover how massive this population was and to find that they were still actively migrating for weeks and weeks after birth.”

    To determine whether these immature neurons — which the researchers dubbed “the Arc” — actively migrate in the newborn brain, researchers used viruses to label immature neurons in tissue samples collected immediately after death and observed that Arc cells move inch-worm style through the brain, much as neurons migrate in the fetal brain.

    Further histological studies of the cingulate cortex, a portion of the brain’s frontal lobe, show that Arc neurons migrate outward from the ventricles into the cortex primarily within the first three months of life, where they differentiate into multiple different subtypes of inhibitory neurons.

    “It is impressive that these cells can find their way to precise positions within the cortex,” said Alvarez-Buylla. “Earlier in fetal development the brain is much smaller and the tissue far less complicated, but at this later stage it is quite a long and treacherous journey.”

    Late migration of inhibitory neurons could play a role in human cognitive abilities, neurological disease

    Inhibitory neurons, which use the neurotransmitter GABA, make up about 20 percent of the neurons in the cerebral cortex and play a vital role in balancing the brain’s need for stability with its ability to learn and change. Imbalanced excitation and inhibition — particularly in circuits of the frontal lobe of the brain, which are involved in executive control — have been implicated in many neurological disorders, from autism to schizophrenia.

    The new research suggests that inhibitory circuits in humans develop significantly later than previously realized. This postnatal migration is much larger than what is seen in mice and other mammals, the authors say, suggesting that it may be an important developmental factor behind the uniqueness of the human brain.

    The first months of life, when an infant first begins to interact with its environment, is a crucial time for brain development, Huang said. “The timing of this migration corresponds very well with the development of more complex cognitive functions in infants. It suggests that the arrival of these cells could play a role in setting up the basis for complex human cognition.”

    The researchers plan to follow up their study by exploring whether this migration of inhibitory neurons from the Arc to the cortex might be affected in the brains of children with neurological disorders such as autism, which has previously been associated with abnormal inhibitory circuitry in the frontal cortex.

    “Trying to understand what makes human brain development so unique was what drove me to tackle this research,” said Paredes, who works with patients with epilepsy in her clinical practice. “If we don’t understand how our brains are built, we won’t be able to understand what is going wrong when people suffer from neurological disease.”

    Other UCSF authors on the paper are David James, Hosung Kim, PhD, Jennifer A. Cotter, MD, Carissa Ng, PhD, Kadellyn Sandoval, David Rowitch, MD, PhD, and Patrick S. McQuillen, MD, PhD.

    This work was sponsored by a generous gift from the John G. Bowes Research Fund. Alvarez-Buylla is the Heather and Melanie Muss Endowed Chair of Neurological Surgery at UCSF. Additional research funds were provided by National Institutes of Health research grants (RO1 HD032116-21, PO1 NS083513-02, R01EB009756, R01HD072074, 2R01 NS060896) and training grants from the NIH (MBRS-RISE R25-GM059298, K08NS091537-01A1) and from the California Institute of Regenerative Medicine (TG-01153 and TB1-01194), the Spanish Institute of Health Carlos III (ISCIII2012-RD19-016), a Rio Hortega fellowship (CM12/00014), Banting and FRS Canadian fellowships, the Economics and Competitivity Ministry of Spain (BFU2015-64207-P) and a Generalitat Valenciana grant (PrometeoII 2014-075).

    Happy babies.
  • 10 foods you should eat regularly to maintain healthy liver

    {The liver is a key organ in the digestive system. It’s important you take proper care of your liver because everything you eat or drink passes through it.}

    Here are 10 foods you should eat regularly to maintain a healthy liver

    {{1. Walnuts }}

    Walnuts are good for the liver because they contain glutathione and omega-3 fatty acids which help support the liver through its cleansing process.

    {{2. Garlic }}

    Garlic is good for the liver because they contain high amounts of allicin and selenium which aid in liver cleansing.

    {{3. Turmeric }}

    Turmeric is mostly used as a spice but it can also act as a natural form of detox for the liver.

    {{4. Grapefruit }}

    Eating grapefruit is good for the liver because it helps the liver flush out carcinogens and toxins.

    {{5. Lemon }}

    Lemon is another food which helps maintain a healthy liver. Lemons help cleanse the body of toxic materials and also aid the digestion process.

    {{6. Avocados }}

    Avocados are good for the liver because they contain a type of antioxidant known as glutathione which helps the liver filter out harmful products.

    {{7. Broccoli }}

    Broccolli helps us maintain a healthy liver by increasing the amount of glucosinolate in the body that helps create enzyme for digestion.

    {{8. Green tea }}

    Green tea consumption is good for the liver because green tea contains antioxidants known as catechins which help improve liver function.

    {{9. Leafy greens }}

    Leafy greens such as spinach and lettuce are good for the liver.

    {{10. Beefs }}

    Beets are good for the liver because they contain flavonoids which improve liver function.

  • Ladies…5 ways to keep your privates feeling fresh

    {Are you having issues with keeping your privates fresh? It could really be frustrating and embarrassing when you don’t feel fresh down there.}

    I got some tips that will help every woman feel fresh down there

    {{1. Pee after sex }}

    If you don’t normally pee after sex, you aren’t really helping your privates. Peeing after sex helps keep your privates fresh by helping you avoid urinary tract infection.

    {{2. Eat fruits }}

    Various reports claim eating lots of fruits especially pineapple and strawberries helps keep a woman’s privates fresh and makes it smell good too. Whether the reports are actually true or not, eating fruits will help you stay healthy and staying healthy is also good news for your privates.

    {{3. Don’t stay in wet clothes for too long }}

    Avoid staying in wet clothes for too long especially after working out. Wearing your work out clothes for too long after working put increases your chances of getting a yeast infection.

    {{4. Don’t douch }}

    Stay away from douching because it causes more harm than good to your privates. Douching upsets the pH balance of your privates causing irritation, inflammation and infection.

    {{5. Switch to cotton underwear }}

    While silk underwear make you look really sexy, they aren’t really good for your privates because they are not breathable thereby increasing the risk of moisture being trapped which can cause a yeast infection. Switch to cotton underwear.

  • Certain LDL-C-lowering genetic variants associated with higher risk of type 2 diabetes

    {In a study appearing in the October 4 issue of JAMA, Luca A. Lotta, M.D., Ph.D., of the University of Cambridge, U.K., and colleagues examined the associations with type 2 diabetes and coronary artery disease of low-density lipoprotein cholesterol (LDL-C)-lowering genetic variants. Treatment with statins, the pharmacological agents of choice for LDL-C-lowering therapy in cardiovascular prevention, is associated with weight gain and a higher incidence of new-onset type 2 diabetes.}

    The researchers conducted a meta-analyses of genetic association studies, and included 50,775 individuals with type 2 diabetes and 270,269 controls and 60,801 individuals with coronary artery disease and 123,504 controls. Data collection took place in Europe and the United States between 1991 and 2016.

    The authors found that LDL-C-lowering genetic variants at the gene NPC1L1 were inversely associated with coronary artery disease and directly associated with type 2 diabetes. For a given reduction in LDL-C, genetic variants were associated with a similar reduction in coronary artery disease risk. However, associations with type 2 diabetes were heterogeneous (dissimilar), indicating gene-specific associations with metabolic risk of LDL-C-lowering alleles.

    “In this meta-analysis, exposure to LDL-C-lowering genetic variants in or near the NPC1L1 gene was associated with a higher risk of type 2 diabetes,” the authors write.

    “The results of this study show that multiple LDL-C lowering mechanisms, including those mediated by the molecular targets of available LDL-C-lowering drugs (i.e., statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors), are associated with adverse metabolic consequences and increased type 2 diabetes risk.”

    “In general, unlike the association of LDL-C-lowering alleles [an alternative form of a gene] with cardiovascular risk, the association of these alleles with metabolic risk appears to be specific to particular genes, which in turn might suggest that the adverse consequences of lipid-lowering agents on diabetes risk could be specific to a particular drug target. This may have clinical implications for the future of lipid-lowering therapy in the context of the increasing number of approved drugs acting on different molecular targets. The overall safety profile of these drugs, including the magnitude of risk of new-onset type 2 diabetes, may be relevant to the choice of specific agent for subsets of the patient population (e.g., those at high risk for type 2 diabetes who are candidates for lipid-lowering therapy),” the researchers write.

    Treatment with statins, the pharmacological agents of choice for LDL-C-lowering therapy in cardiovascular prevention, is associated with weight gain and a higher incidence of new-onset type 2 diabetes, say researchers.
  • 7 signs of breast cancer you should know

    {Breast cancer is a killer that has taken many lives year after year. The major problem of this cancer is that many people don’t pay attention to it on time, and even when they see signs, they take it for granted.
    }
    Jackie Harris of Breast Cancer Care says: “It’s really important to get to know your breasts so you can spot anything that isn’t normal.

    “Any change is worth getting checked out.”

    Eluned Hughes of Breast Cancer Care adds: “The earlier breast cancer is found, the better the chances of beating it. It’s important to recognise the different signs and check your breasts regularly.”

    The Sun shared 7 experiences of people, including a man who had breast cancer but didn’t know until they went for a checkup in the hospital. Read their experience below and learn from it.

    {{Nicole Reece}}

    “I had never had problems with my skin when I noticed a large patch of flaky skin around my right nipple. I used all kinds of creams from the pharmacy and I just assumed it would go in time.

    “A year later, my nipple had started to crack and my breast looked distorted.

    “I was referred to hospital and had a mammogram, ultrasound and biopsy which confirmed I had a 5cm cancerous tumour.

    “I was stunned. I was in my twenties and had no family history of cancer.

    “I needed a mastectomy, reconstruction, chemotherapy and radiotherapy. I now take Tamoxifen tablets, too.

    “It is so important to check your breasts, not just for lumps but for other abnormalities. I didn’t know a rash could be a sign of breast cancer. Had I not acted on it, it could have been fatal.”

    {{Gill Crutcher}}

    “I was first diagnosed in 2002 after I had a crawling sensation in my left breast that wouldn’t go away. The skin also started to dimple and I realised it wasn’t normal. Tests revealed I had a tiny lump and it was cancerous.

    “At 49, I was surprised to have breast cancer and it took some getting used to. I had the lump removed, and radiotherapy, and all looked fine. But two years ago I noticed a change in my right breast – there appeared to be a ridge on the lower side. At first I thought it was because my bra was too tight. But tests showed I had grade-3 breast cancer.

    “I had the lump removed, and chemotherapy which made me really sick. I’m still on medication but things are better. Please don’t ignore any changes in your breasts. Spotting changes early and acting on it could save your life.”

    {{Becky Leach}}

    “I first noticed something was wrong with my left boob when my nipple started going inwards. I wasn’t too worried at first but when I found a small lump, which started to grow, I went to the doctor who referred me to a breast clinic.

    “I had an ultrasound, a mammogram and biopsy and got told on the same day it was highly likely I had breast cancer. It was like a bomb going off and it was hard to tell people I was having a mastectomy, reconstruction and chemotherapy.

    “I struggled with chemo – it made me sick and tired. But online support groups helped.

    “It is vital you get into the habit of checking your boobs and know what to look out for. And if something isn’t normal for you, go and get it checked out.

    “Things might not have been the same for me if I had delayed seeing my doctor.”

    {{Stuart Weaver}}

    “Many people aren’t aware blokes can get breast cancer – but I did. When I was 36, I noticed a lump on the left side of my chest which didn’t go away. I thought it was a fatty mass or a cyst but my wife encouraged me to go to the doctor.

    “I was referred for hospital tests and was stunned to find out it was cancerous. I had a mastectomy, all my lymph nodes removed, followed by chemotherapy and radiotherapy. I was really nervous about the surgery but it was fine. They took away the nipple, and my chest hair doesn’t grow like it used to, but the scar has faded a lot.

    “The cancer then came back four years ago, spotted at my regular check-up, and I still take medication. I would urge anyone – male or female – to regularly check their chest for anything unusual.

    “It is always better to be safe than sorry.”

    {{Alex Jones}}

    “I was 21 when I noticed stains in my bras from nipple discharge. I never knew this was a symptom of breast cancer. I later found a lump under my right breast and went to A&E. But the doctor told me I had lumpy boobs and not to worry.

    “When I turned 23, the discharge was bloody and I felt pain in my armpit. My GP referred me for tests which revealed I had breast cancer. I had treatment to freeze my eggs, then had a mastectomy, chemotherapy and reconstruction.

    “Although it looked like the cancer had gone, doctors then told me last year that it has returned, spread and is incurable. I’m having chemo to keep it at bay for as long as I can and a tumour in my lung has shrunk but the cancer is in my bones and liver.

    “Please know all the signs of breast cancer and be persistent if you get dismissed by medics.”

    {{June Love}}

    “I lifted my arm up to brush my hair after having a shower, when I noticed an indentation in my left breast.

    “I mentioned it to my doctor when I went for my usual check-up. I saw a specialist less than a week later, when I had a CT scan, mammogram and biopsy.

    “The tests showed I had a 2cm cancerous tumour behind my nipple and I was told I needed a mastectomy, chemotherapy and my lymph nodes removing.

    “It was hard to come to terms with everything, especially because I’d just lost my mum to bowel cancer and my son was working abroad. Fortunately, treatment seems to have worked. All of my mammograms have been clear.

    “I knew that any change to the breast could mean cancer. So make sure you know yours well enough to act – and act fast if you spot something.”

    {{Sara Larkin}}

    “I’ve always been really aware of breast cancer after my grandmother had it. I always knew the importance of checking.

    “I noticed a lump in my armpit last year. When it didn’t go away, I went to my GP. They first said it looked like a lymph node infection and would go.

    “But when a second one appeared, I was referred for tests. A blood check revealed nothing but I was diagnosed with breast cancer after having a biopsy.

    “I wasn’t aware that women of 29 could get breast cancer.

    “I froze my eggs before starting chemotherapy, which made me really sick. It felt like the worst hangover of my life. Now I’m having six-monthly check-ups to make sure all is OK.

    “It’s vital that women of all ages are aware of all the signs of breast cancer and check their breasts regularly.”

  • Retroviral diseases: Children who keep HIV in check

    {Some HIV-infected — and untreated — children do not develop AIDS. A new study shows that they control the virus in a different way from the few infected adults who remain disease-free, and sheds light on the reasons for this difference.}

    Children who are HIV-positive but remain free of AIDS are very rare. In the absence of antiretroviral therapy, over 99% of individuals infected with HIV go on to develop full-blown AIDS, and the condition evolves more rapidly in children than in adults. However, between 5 and 10% of perinatally infected HIV-positive children avoid this fate, as an international research collaboration, led by Dr. Maximilian Muenchhoff at LMU’s Max von Pettenkofer Institute and colleagues based at the University of Oxford (Professor Philip Goulder), report in the current issue of the journal Science Translational Medicine. The group has characterized the immunological responses of a cohort of these so-called non-progressors — HIV-positive children in South Africa who contracted the infection from their mothers but who remain healthy. At the time of the study, the average age of the cohort was just under 8½ years old.

    The investigations reveal that these children have high concentrations of circulating HIV particles, although their immune system remains fully functional. “Interestingly however, these infected but healthy children exhibit only low levels of immune activation. In addition, while the spectrum of cell types that contain the virus — the so-called viral reservoir — is very complex it is predominantely restricted to short-lived CD4+ T cells in these young non-progressors,” says Dr. Maximilian Muenchhoff. In addition, the researchers found that most of these children have high levels of potent and broadly neutralizing antibodies directed against HIV.

    These features of the immune response in healthy HIV-infected children show a striking resemblance to that observed in the more than 40 species of African monkeys which are the natural hosts of Simian Immunodeficiency Virus (SIV) — from which HIV itself is derived. Although the virus replicates very efficiently in these primates, infected animals show no signs of immune dysfunction. Here too, short-lived CD4+ T cells serve as the primary viral reservoir, and levels of immune activation are low, as seen in the study cohort. In contrast to this picture, the vast majority of HIV-infected AIDS patients, both adults and children, display all the signs of chronic activation of the immune system. Furthermore, this condition persists even under anti-retroviral therapy which effectively reduces viral numbers, and it is also associated with long-term complications, such as an increased risk of cardiovascular disease.

    The new findings are therefore of interest not only with respect to the development of effective HIV vaccines, they may also provide pointers toward potential interventions for patients with chronic HIV infections. “This is a remarkable clinical study from the epicenter of the HIV pandemic. The ability of these children to maintain an intact immune system in the face of ongoing viral replication and in the absence of antiretroviral therapy can provide us with new insights into hitherto unknown defense mechanisms, which could eventually benefit other HIV patients,” says Professor Oliver T. Keppler, Chair of Virology at the Pettenkofer Institute, and former head of the German Reference Center for Retroviruses in Frankfurt am Main.

    The 170 members of the study cohort in Durban, South Africa, were infected with HIV by mother-to-child transmission. However, since these children showed no symptoms of disease, the fact that they were infected was, in most cases, discovered only several years later when their mothers had developed AIDS and sought medical attention.

    Children who are HIV-positive but remain free of AIDS are very rare. In the absence of antiretroviral therapy, over 99% of individuals infected with HIV go on to develop full-blown AIDS, and the condition evolves more rapidly in children than in adults. However, between 5 and 10% of perinatally infected HIV-positive children avoid this fate.
  • HIV cure hope thanks to collaboration

    {Researchers are hopeful of a cure for HIV after treating the first patient with a promising new treatment that could kill all traces of the virus.}

    A partnership sparked by the National Institute for Health Research (NIHR) is behind this collaborative UK effort for the new treatment, which is a first-of-its-kind.

    Six years ago this month, a meeting took place between five leading UK research establishments which resulted in a shared commitment to find a cure for HIV.

    A partnership sparked by the National Office for Clinical Research Infrastructure (NOCRI), part of the NIHR, identified in that meeting that while there is research into treatment of HIV, as there is for many chronic conditions, there was no research into eradication of the disease.

    Each of the British research institutions present — Oxford University, University of Cambridge, Imperial College London, King’s College London and University College London — agreed that they could provide a part of the jigsaw needed to find the cure, but could not achieve this in isolation.

    Managing Director of NOCRI Mark Samuels said: “This was a meeting of some of the UK’s top medical research leaders and it was a privilege to encourage joining forces.

    “We understand the power in brokering crucial relationships to pioneer health breakthroughs, and this meeting was a prime example of that.

    “Together, we identified a research need which could only be achieved by creating a collaboration between these leading establishments.

    “The competitive nature of the relationship between Oxford and Cambridge, spanning 800 years, is widely known, but there is also competition running across all these leading universities, particularly in terms of vying for research funding.

    “Yet here was an opportunity to put that competition aside, and collaborate on a global health challenge. As a result, the Medical Research Council awarded one of the first joint grants to these five leading biomedical research institutions.

    “And in return each research centre provides its expertise to complete the jigsaw needed to find a cure for HIV — from patients, to the right doctors, the right diagnostic technology, the mathematician to analyse results and so on. CHERUB was born.”

    CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC) is a new approach to HIV therapeutics in the UK.

    It is one of the first co-operatives of UK Biomedical Research Centres to engage internationally in one of the most exciting new fields of biomedical research — that of HIV cure.

    CHERUB brings together, amongst others, clinicians, virologists, immunologists, molecular biologists and mathematical modellers under the umbrella of the NIHR.

    Over 30 medical researchers attended a kick-off meeting, and it was acknowledged that so many world-leaders in the field had never been in one room together, even on the conference circuit.

    This collaboration is the most significant attempt to find a cure for HIV in the UK.

    And in the six years since, great progress has been made. The ‘Kick and Kill’ study will recruit 50 HIV study participants, in which researchers activate HIV infected cells which are ‘asleep’.

    By waking them and treating them with an HDAC inhibitor drug, the body’s own immune system is encouraged to fight the disease.

    HIV is a virus infection that is treatable using Antiretroviral Therapy (ART). ART works by stopping HIV from copying itself and spreading. ART reduces the amount of virus in the blood stream to such low levels that it prevents the virus from being passed on to others, and gives the body’s immune system a chance to recover.

    But ART alone cannot cure HIV. This is because it only works on HIV infected cells that are active, and most cells infected with HIV in the human body contain resting or sleeping virus. These cells represent an invisible reservoir of HIV, and are one of the reasons it is so difficult to cure the infection. If ART is stopped, usually the virus returns.

    There is a strong interest amongst people living with HIV, as well as researchers, to look at different ways that could help to cure HIV and allow people to remain healthy without needing lifelong medication.

    Sarah Fidler, Professor of HIV and Communicable Diseases at Imperial College London and co-Principal Investigator on the study, said: “This first participant has now completed the intervention and we have found it to be safe and well tolerated. Only when all 50 study participants have completed the whole study, by 2018, will we be able to tell if there has been an effect on curing HIV. Professor John Frater’s lab in Oxford will lead on the tests and assays to determine if the trial has had an effect.”

    Professor Jonathan Weber, Chair of CHERUB Scientific Steering Committee and Director of Research for the Faculty of Medicine at Imperial College London, said: “CHERUB has made great progress since it was born six years ago. We are now actively recruiting patients to test the ‘Kick and Kill’ theory.

    “NOCRI was instrumental to this research starting. We are all thoroughly committed to finding a cure for HIV, but if the collaboration between this set of HIV researchers had not been prompted at that meeting six years ago, this simply would not have happened.”

    The NIHR Office for Clinical Research Infrastructure (NOCRI) brings world-leading investigators, scientific industries and research facilities together, acting as a catalyst to make vital research happen.

    By brokering crucial relationships, NOCRI helps deliver pioneering health breakthroughs, bringing drugs, devices and diagnostics to patients faster.

    Further information from the research team

    In response to the recent attention in the media regarding the RIVER study run by the UK CHERUB collaboration, we would like to provide some additional detail.

    Our study will report in 2018, and at that point we will know if the intervention has had an effect. We already know that the intervention was well tolerated in our first participant and we await the results of further participants. This is the first time that this combination has been given in a clinical trial, which we hope will be the first of many collaborations exploring HIV cure between our five universities and NHS hospital trusts, supported by the NIHR.

    It is important to note that all participants involved in the study will be expected to have no HIV in their blood because they are receiving antiretroviral therapy — these are the standard drugs we use to treat HIV. Although this does not mean they have been cured as some headlines have suggested, it does mean that their immune systems will recover and that they will not transmit the virus. We look forward to reviewing the final results of this ground-breaking study, it will be at that point that we will be able to say whether any individual has responded to the intervention or been cured.

    HIV/AIDS definition illustration
  • Why do men want sex in the morning

    {Have you ever wondered why most women want sex so bad at night and most men want sex so bad in the morning?}

    When most women want their man so bad at night, he just wants to sleep and when most men want their woman so bad in the morning, she just wants to go back to sleep. What could really be the problem?

    This difference between the time men and women want sex is due to hormones.

    A man’s testosterone levels are at its peak even before he wakes up in the morning. This is because the pituitary gland which governs the production of the male sex hormones has been switched on in the night and the level has been steadily rising until dawn.

    Most men would wake up hard two or three times in a week due to the raised testosterone levels in the morning.

    This is why he would want sex with his partner early in the morning.

    But while a man’s testosterone levels are at its highest when he wakes up, that of women are usually at their lowest in the morning.

    Men’s testosterone levels starts to fall gradually as evening approaches while that of women gradually rises.

    Towards 10PM, a man’s testosterone levels are at its lowest point in the day while a woman’s testosterone levels are at its highest.

    Even though the man’s testosterone levels are at its lowest point in the day, men are still likely to have sex because a man’s testosterone level is still running higher than a woman’s testosterone even though hers is at its highest.

    According to experts, a woman’s testosterone levels are at its highest during the 13th day of her cycle. This means she would climax more intensely and it would be felt all over the body.

  • Do you feel thirsty before you sleep at night?Researchers have found the reason why

    {According to a study published in the journal Nature by McGill University researchers, the brain’s biological clock stimulates thirst in the hours before sleep.}

    The research was conducted on mice. Scientists knew that rodents show a surge in water intake during the last two hours before sleep. The study revealed that this behaviour is not motivated by any physiological reason, such as dehydration. So if they don’t need to drink water, why do they?

    The research found that restricting the access of mice to water during the surge period resulted in significant dehydration towards the end of the sleep cycle. So the increase in water intake before sleep is a preemptive strike that guards against dehydration and serves to keep the animal healthy and properly hydrated.

    “Although this study was performed in rodents, it points toward an explanation as to why we often experience thirst and ingest liquids such as water or milk before bedtime,” Bourque says. “More importantly, this advance in our understanding of how the clock executes a circadian rhythm has applications in situations such as jet lag and shift work. All our organs follow a circadian rhythm, which helps optimize how they function. Shift work forces people out of their natural rhythms, which can have repercussions on health. Knowing how the clock works gives us more potential to actually do something about it.”

    In essence, you don’t really feel thirst before sleep because you are thirsty; it’s only your brain sending thirst signals to take precaution.

  • Details of mysterious Utah Zika-related death: Transmission by tears or sweat

    {The first Zika virus-related death in the continental U.S. occurred in June of this year, but even now, months later, two aspects of this case continue to puzzle health experts. First, why did this patient die? It is quite rare for a Zika infection to cause severe illness in adults, much less death. Second, how did another individual, who visited the first while in the hospital, become ill from Zika? This second patient did not do anything that was known at the time to put people at risk for contracting the virus.}

    Researchers at the University of Utah School of Medicine and ARUP Laboratories in Salt Lake City begin to unravel the mystery in a correspondence published online on Sept. 28 in The New England Journal of Medicine. Details from the two cases point to an unusually high concentration of virus in the first patient’s blood as being responsible for his death. The phenomenon may also explain how the second patient may have contracted the virus by touching the tears or sweat from the primary patient, the first such documented case.

    “This rare case is helping us to understand the full spectrum of the disease, and the precautions we may need to take to avoid passing the virus from one person to another in specific situations,” says corresponding author Sankar Swaminathan, M.D., Chief of Infectious Disease and Professor of Internal Medicine at the University of Utah School of Medicine. He collaborated with coauthors Robert Schlaberg, M.D., M.P.H., Marc Couturier, Ph.D., and Kimberly Hanson, M.D., M.H.S. from ARUP Laboratories, and Julia Lewis, D.O. from the University of Utah School of Medicine. “This type of information could help us improve treatments for Zika as the virus continues to spread across the world and within our country.”

    From the letter in NEJM, a story unfolds. Last May, Patient 1, a 73-year-old man, traveled to southwest Mexico, a Zika-infected area. Eight days after returning, he started having abdominal pain and fever, and by the time he was admitted to the University of Utah hospital he also had inflamed, watery eyes, low blood pressure and a rapid heart rate. Despite the medical staff’s best efforts to stabilize him, his condition declined rapidly. During this time, Patient 2 came to visit and reported wiping away Patient 1’s tears and helping to reposition him in the hospital bed. It wasn’t long before Patient 1 slipped into septic shock, and his kidneys, lungs and other organs started to shut down. He died shortly thereafter.

    Even though it’s well known that Zika can cause severe brain damage in unborn babies, symptoms are typically mild in adults. Only nine other Zika-related deaths have been reported worldwide, says Swaminathan. Despite the odds, tests performed after Patient 1’s death revealed that he had Zika. Patient 1 was initially identified as being potentially infected with Zika virus during validation of a real time PCR test for Zika virus that is currently under development at ARUP Laboratories, and was subsequently confirmed as positive by both the Utah Department of Health and the Centers for Disease Control and Prevention.

    Further investigation using Taxonomer, a tool developed by scientists at University of Utah and ARUP Laboratories, that rapidly analyzes all genetic material from infectious agents in a patient’s sample, showed there were no other infections that explained his illness. It also found that the Zika virus that infected the patient was 99.8 percent identical to that carried by a mosquito collected from southwest Mexico, the same region that Patient 1 had visited a few weeks prior.

    Seven days after Patient 1’s death, Patient 2 was meeting with Swaminathan to talk about what had happened when the doctor noticed that his visitor had red, watery eyes, a common Zika symptom. Tests confirmed his suspicion, but in contrast to Patient 1 this patient only had mild symptoms that resolved within the following week.

    Like Patient 1’s death, Patient 2’s diagnosis was unexpected. The species of mosquito that carries Zika had not been found in Utah and Patient 2 had not traveled to a Zika-infected area. A reconstruction of events ruled out other known means of catching the virus.

    “This case expands our appreciation for how Zika virus can potentially spread from an infected patient to a non-infected patient without sexual contact or a mosquito vector,” says Couturier. “This and any future cases will force the medical community to critically re-evaluate established triage processes for determining which patients receive Zika testing and which do not.”

    The authors believe that the reason behind the unusual nature of the case lies in yet another anomaly. Patient 1’s blood had a very high concentration of virus, at 200 million particles per milliliter. “I couldn’t believe it,” says Swaminathan. “The viral load was 100,000 times higher than what had been reported in other Zika cases, and was an unusually high amount for any infection.” The observation opens up the possibility that the extraordinary amount of virus overwhelmed the patient’s system, and made him extremely infectious.

    Still, what led to the unusually severe infection in the first place remains unknown. Was there something about Patient 1’s biology or health history that made him particularly susceptible? There were small differences in the virus’ genetic material compared to other samples of Zika virus, did they cause the virus to be exceptionally aggressive?

    “We may never see another case like this one,” says Swaminathan. “But one thing this case shows us is that we still have a lot to learn about Zika.”

    Two new cases show there is still more to learn about Zika.